Thousands of Australians with multiple sclerosis, asthma and diabetes will benefit from the listing or extension of several medications on the Pharmaceutical Benefits Scheme (PBS). Federal Member for Page Kevin Hogan said this is bringing further support to patients and their families. From March 1, Zeposia® and Atecture Breezhaler® was listed on the…
Australians with a rare, fatal heart condition will soon have subsidised access to a ground-breaking medicine for the first time, thanks to its new listing on the Pharmaceutical Benefits Scheme (PBS). Federal Member for Page Kevin Hogan said from today Uptravi® (selexipag) will be PBS listed for the first time to treat Pulmonary Arterial…
Australian adults living with Attention Deficit Hyperactivity Disorder (ADHD) will soon have more affordable access to a life-changing treatment option, thanks to its expanded listing on the Pharmaceutical Benefits Scheme (PBS). Federal Member for Page Kevin Hogan said from today the Government is expanding the listing of Vyvanse® (lisdexamfetamine) to include patients who are…
The first day of the new year brought with it new hope for Australians fighting one of the most common blood cancers, thanks to a critical new medicine listed on the Pharmaceutical Benefits Scheme (PBS).On 1st January 2021, Darzalex® (daratumumab) was listed for the first time in combination with bortezomib and dexamethasone, as a second-line…
A significant lung cancer treatment option that costs approximately $88,000 a year will soon be available for as little as $6.60 per script, thanks to its expanded listing on the Pharmaceutical Benefits Scheme (PBS). From 1 January 2021, Australians living with non-small cell lung cancer who have not had prior therapy will benefit from the listing…
Patients living with one of Australia’s most common forms of leukaemia are set to benefit from expanded access to a breakthrough medicine through the Pharmaceutical Benefits Scheme (PBS). From 1 December, access to Venclexta® (venetoclax) will be extended in combination with obinutuzumab for the first-line treatment of patients with chronic lymphocytic leukaemia who have…
Access to a life-saving and life-changing medicine will soon be expanded for Australian children and infants with Spinal Muscular Atrophy (SMA). From 1 December, subsidised access to the life-changing medicine Spinraza® (nusinersen) will be expanded on the Pharmaceutical Benefits Scheme (PBS). It will include children and infants genetically diagnosed with the most severe types…
A key new cancer treatment has just become more accessible for Australians fighting specific forms of leukaemia and lymphoma Federal Member for Page Kevin Hogan said the Federal Government has listed Calquence® on the Pharmaceutical Benefits Scheme (PBS). Calquence® (acalabrutinib) has been listed on the PBS for the first time for the treatment…
Australians suffering from melanoma and multiple sclerosis have new treatment options, with new and amended PBS listings. 🔸 Tafinlar® (dabrafenib) and Mekinist® (trametinib) will be extended to include subsidy for post-surgery treatment for patients who have Stages IIIB, IIIC and IIID melanoma. 🔸 Gilenya® (fingolimod) will be amended to include a new strength of this medicine for…
Cheaper medicine is avaliable for more than 500,000 patients, with price reductions for common scripts and new medicines added to the Pharmaceutical Benefits Scheme (PBS), the Federal Member for Page Kevin Hogan said. “In some cases this will save over $100,000 per patient,” “Medicines to treat lung cancer, lymphoblastic and acute leukaemia, and nausea associated…